Finasteride for prostatic disease: An updated and comprehensive review

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 12, 2008, Pages 1561-1568

  De Nunzio, Cosimo ^a   Miano, Roberto ^b   Trucchi, Alberto ^a   Agrò, Enrico Finazzi ^b   Tubaro, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Benign prostatic hyperplasia; Finasteride; Prostate cancer; Prostatitis; Treatment

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CYTOCHROME P450; DIGOXIN; DOXAZOSIN; FINASTERIDE; PHENAZONE; PLACEBO; PROPRANOLOL; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ALLERGIC REACTION; ANGINA PECTORIS; ASTHENIA; BONE DENSITY; BRONCHITIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; EJACULATION DISORDER; ENZYME INHIBITION; ERECTILE DYSFUNCTION; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; GLEASON SCORE; GYNECOMASTIA; HEADACHE; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; INFLUENZA; INHIBITION KINETICS; LIBIDO DISORDER; LIPID BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MEDICAL RESEARCH; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PROLACTIN BLOOD LEVEL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATITIS; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SEMEN ABNORMALITY; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; TERATOGENICITY; TESTOSTERONE SYNTHESIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE FLOW RATE; URINE INCONTINENCE; URINE RETENTION;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; META-ANALYSIS AS TOPIC; PROSTATIC DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 58149195300     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802587058     Document Type: Review

References (44)

1. Barry MJ, Roehrborn CG. Extracts from "Clinical Evidence": Benign prostatic hyperplasia. BMJ 2001;323:1042-6
2. Mc Connell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guide1 Quick Ref Guide 1994;8:1-17
3. Chatelain C, Denis L, Foo JKT, et al. Evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. In: Benign Prostatic Hyperplasia. Chatelain C, Denis L, Foo KT, et al. editors, Health Publication Ltd, Plymouth, UK; 2001. p. 519-34
4. Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin 2008;58:71-96
5. D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol 2006;176:2010-2
6. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:20
7. Mc Connell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74(3):505-8
8. Foley CL, Kirby RS. 5 Alpha-reductasi inhibitors: what's new? Curr Opin Urology 2003;31-7
9. Roehrborn CG. 5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. Rev Urol 2003;5(5):12-21
10. Finasteride prescription drug information. Available from: www.fda.gov
11. McConnell JD, Bruskewitz RC, Walsh P, et al. for The Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63
12. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51(5):677-86
13. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-98
14. Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. Curr Opin Urol 2004;14(1):17-20
15. Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992;147(5):1298-302
16. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327(17):1185-91
17. Boyle PA, Gould L, Roehrborn CG, Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48(3):398-405
18. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999;54(4):662-9
19. Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997;49(6):839-45
20. Khan MA, Partin AW. Finasteride and prostate cancer. Rev Urol 2004;6(2):97-8
21. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-24
22. Andriole GL, Humphrey PA, Serfling RJ, et al. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artefact? J Natl Cancer Inst 2007;99:1355-6
23. Greene D, Page T. Why do men who receive finasteride have an increased prevalence of high-grade prostate cancer? Nat Clin Pract Urol 2008;5:130-1
24. Goodman PJ, Thompson IM, Tangen CM, et al. The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol 2006;175(6):2234-42
25. Redman MW, Tangen CM, Goodman PJ, et al. Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach. Cancer Prev Res 2008;1:174-81
26. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83
27. Lucia MS, Darke AK, Goodman PJ, et al. Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention. Cancer Prev Res 2008;1:167-73
28. Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177(5):1749-52
29. Thompson IM, Chen C, Donna P, et al. Effect of Finasteride on the sensitivety of PSA for detection of prostate cancer. J Natl Cancer Inst 98(16):1128-33
30. De Vere White. Finasteride for Chemoprevention of Prostate Cancer: Why Has It Not Been Embraced? JCO 2007;25(21):2999-3000
31. Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1025-35
32. Roehrborn CG, Lotan Y, Tabaro A, et al. The motion: Prevention of prostate cancer with a 5α-reductase inhibitor is feasible. Eur Urol 2006;49(2):396-400
33. Svatek RS, Lee JJ, Roehrborn CG, et al. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008;112:1058-65
34. Svatek RS, Lee JJ, Roehrborn CG, et al. Cost effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Urol Oncol 2008;26(5):564-5
35. Thompson IM, Tangen CM, Lucia MS. The Prostate Cancer Prevention Trial and the future of chemoprevention. BJU Int 2008;101:9333-4
36. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia. a preliminary report. J Urol 1995; 154(5):1779-82
37. Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998;51(2):237-40
38. Kearney MC, Bingham JB, Bergland R, et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002; 167(6):2489-91
39. Holm M, Meyhoff HH. Chronic prostatic pain. A new treatment option with finasteride?" Scand J Urol Nephrol 1997;31(2):213-5
40. Nickel JC, Downey J, Pontari MA, et al. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatiris). BJU Int 2004;93(7):991-5
41. AUA guideline on management of benign prostatic hyperplasia. J Urology 2003;170:530-47
42. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995;46(5):631-7
43. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996;155(9):1251-9
44. Lowe FC, Mc Connell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2004;61(4):791-6.